Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
1. ROIV's brepocitinib showed significant improvement in dermatomyositis Phase 3 trial. 2. Brepocitinib achieved a TIS of 46.5 versus 31.2 for placebo. 3. Positive results support filing for NDA in 2026 for brepocitinib. 4. 75% of patients on steroids saw reduced doses with brepocitinib treatment. 5. ROIV stock rose by 11.11%, indicating positive market reception.